FOOTHILL RANCH, Calif.--(BUSINESS WIRE)--TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that Bruce Bauer, Chief Executive Officer, will present at the 22nd Annual Southern California Biomedical Council (SoCalBio) Conference.
Date: Friday, October 23, 2020
Time: 11:15 - 11:27 AM PST
TLS’ presentation is part of the Nurturing Innovators track that showcases emerging biosciences companies. Mr. Bauer will provide an overview of the company and its recent business milestones.
About TAE Life Sciences
TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to cancer patients who need it most. TLS’s drug and device are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com
